FOUNTAIN VALLEY, Calif., May 18, 2021 /PRNewswire/ — Antech Diagnostics announced today the second published study for its Canine CE-IBD assay, veterinary medicine’s first non-invasive blood test for canine chronic enteropathy/inflammatory bowel disease. The new study, published in the Journal of Veterinary Internal Medicine (JVIM) on May 7, 2021, shows that the assay distinguishes CE dogs from non-CE dogs accurately and allows veterinary teams to evaluate a dog’s response to treatment. The growing body of data also demonstrates its value as an easy, effective, first-line diagnostic approach for all dogs with chronic GI symptoms, allowing them to regain good health faster.
Vomiting, diarrhea and related GI signs are among the most common reasons dog owners visit the veterinarian. Determining the cause can be lengthy, frustrating and expensive. If chronic enteropathy, also called inflammatory bowel disease (IBD), is present, a dog’s nutritional status and overall health could be compromised. Conceptualized from the diagnostics that ~85% of gastroenterologists use to diagnose and monitor GI disorders in humans, the Canine CE-IBD assay offers an easy, affordable, effective way to rule in/rule out CE early by measuring serological biomarkers to determine if a dog’s clinical signs are “consistent with CE” or “not consistent with CE.”
“New approaches to identifying and managing CE have long been desired,” said Todd Tams, DVM, DACVIM, chief medical officer for Mars…
